Publications by authors named "Irfana Banu"
Article Synopsis
- The MUSIC trial tested nirsevimab, a monoclonal antibody designed to treat severe RSV infections in immunocompromised children under 24 months, assessing its safety and how the body processes the drug over time.
- Out of the 100 participants with various immunocompromising conditions, most experienced minimal side effects, with three deaths occurring that were unrelated to the treatment.
- Findings showed that nirsevimab was generally well tolerated, with serum levels indicating potential effectiveness in preventing RSV infections similar to those in healthy infants, though some children had increased drug clearance that may affect efficacy.
Article Synopsis
- A study on children with congenital heart disease or chronic lung disease found that 200 mg nirsevimab is as safe as palivizumab for RSV prevention.
- Nirsevimab showed effective serum levels that could help protect healthy infants from severe RSV disease.
- The results suggest that nirsevimab could also be effective for children at high risk of severe RSV during their second RSV season.